New Product Release
Genovis launches FragIT™ Kit, a column product that will enable customers to scale up volumes with very high yields and shorter process times.
This new antibody engineering tool is a further development of Genovis’ unique technology and is targeting pharma-, biotechnology- and diagnostic companies that develop antibody based drugs and analysis . R ead more at: www.genovis.com/FragIT-Kit
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 46 10 12 35 firstname.lastname@example.org
Genovis develops and designs smart nanoparticles for preclinical imaging and diagnostics and also develops and sells tools for modification of antibodies. Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission ( 46 (0)31 745 50 00) is the Company’s certified adviser.